Search
EHA Research Conference 2025
Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson,
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid
Registration is now open
EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…
EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes
The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.
Read moreTutorial on thalassemia focused on best treatment
Almost 90 delegates from Shiraz and other cities in Iran learned how to identify the best treatment for each thalassemia patient at the EHA-SHRC Hematology Tutorial on Thalassemia on May 10-11, 2018 in Shiraz, Iran.
Read moreImpact of new technologies on diagnosis and treatment of anemias highlighted in scientific meeting
Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017 in Barcelona, Spain.
Read moreCommunity and Stakeholder Committee
Current committee members
Raul Córdoba Mascuñano, Spain (Chair)
Donal McLornan, United Kingdom (Vice-Chair)
Meritxell Alberich Jordà, Czech Republic (EHA Board)
Margarita Guenova, Bulgaria (EHA Board)
Nuno Borges, United Kingdom (Representative, Young EHA Committee)
Ivo Touw, The Netherlands (Representative, Education Committee)
Regular members
Daniel Coriu, Romania
Andres Ferreri, Italy
Darko Antic,…
Cancer Medicines Forum workshop April 5: a way forward for treatment optimization
The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).
Read moreFirst CMML guidelines produced by EHA, now available
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.
Read moreClinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »